Kathy Giusti, M.B.A. ’85, founder and CEO of the Multiple Myeloma Research Foundation (MMRF), will address this year's imminent graduates of Harvard Business School as Class Day speaker. She founded the MMRF in 1998 after being diagnosed with multiple myeloma. This spring, Time magazine named her one of the "100 most influential people" in the world. Multiple myeloma is a cancer of plasma cells—white blood cells that produce antibodies; it affects from one to four people per 100,000 and constitutes 1 percent of all cancers. Before starting MMRF, Giusti was an executive with pharmaceutical companies, and she has sought to encourage the development of drugs to treat the disease using a business model, rather than an academic model, of drug development. The MMRF is the world's top funder of myeloma research: it has raised more than $165 million to fund research.
Multiple myeloma research crusader Kathy Giusti to speak at HBS Class Day
Multiple myeloma research crusader Kathy Giusti to speak at HBS Class Day
The founder of the Multiple Myeloma Research Foundation will speak at Harvard Business School Class Day.
You might also like
Ruth J. Simmons Receives the 2026 Radcliffe Medal
Michelle Obama, Drew Gilpin Faust, and others paid tribute to the pioneering educator during Harvard’s Radcliffe Day festivities.
Harvard Elects New Overseers, HAA Directors
Leaders for the governing board and alumni association were chosen by an alumni vote.
Mychal Threets Brings ‘Library Joy’ to Harvard
The librarian and social media star gave the keynote address for Harvard Graduate School of Education’s convocation.
Most popular
Explore More From Current Issue
Harvard Weathers a Year of Turmoil
The federal government has launched unprecedented actions against the University. Here’s a guide.
A Harvard Economist Probes the Affordable Housing Crisis
From understanding gender pay gaps to the housing crisis, Rebecca Diamond’s research aims to improve lives.
A New Black Swan Musical Cranks Up the Tension
The creative team of the A.R.T.’s new show dish on adapting Darren Aronofsky’s thriller classic from screen to stage.